Gene therapy companies have an ethical obligation to develop expanded access policies.

Kearns, Lisa; Chapman, Carolyn Riley; Moch, Kenneth I; Caplan, Arthur L; Watson, Tom; McFadyen, Andrew; Furlong, Pat; Bateman-House, Alison

Kearns, Lisa; Chapman, Carolyn Riley; Moch, Kenneth I; Caplan, Arthur L; Watson, Tom; McFadyen, Andrew; Furlong, Pat; Bateman-House, Alison.

Afiliação

Kearns L; Division of Medical Ethics, NYU Grossman School of Medicine, New York, NY, USA. Electronic address: lisa.kearns@nyulangone.org.
Chapman CR; Division of Medical Ethics, NYU Grossman School of Medicine, New York, NY, USA.
Moch KI; Center for Global Health Innovation, Atlanta, GA, USA.
Caplan AL; Division of Medical Ethics, NYU Grossman School of Medicine, New York, NY, USA.
Watson T; Bionical Emas, Willington, UK.
McFadyen A; The Isaac Foundation, Campbellford, ON, Canada.
Furlong P; Parent Project Muscular Dystrophy, Hackensack, NJ, USA.
Bateman-House A; Division of Medical Ethics, NYU Grossman School of Medicine, New York, NY, USA.

Mol Ther ; 29(4): 1367-1369, 2021 04 07.

Article em En | MEDLINE | ID: mdl-33714373

Assuntos

Biotecnologia/ética; Terapia Genética/ética; Indústrias/ética; Acessibilidade aos Serviços de Saúde/ética; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biotecnologia / Terapia Genética / Indústrias Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google